Achillion Pharmaceuticals Inc Sentiment Increases on Better Stock Potential

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Logo

Sentiment for Achillion Pharmaceuticals Inc (NASDAQ:ACHN)

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) institutional sentiment increased to 1.38 in Q2 2018. Its up 0.43, from 0.95 in 2018Q1. The ratio is better, as 55 institutional investors opened new and increased equity positions, while 40 reduced and sold their stakes in Achillion Pharmaceuticals Inc. The institutional investors in our partner’s database now hold: 105.68 million shares, down from 107.48 million shares in 2018Q1. Also, the number of institutional investors holding Achillion Pharmaceuticals Inc in their top 10 equity positions decreased from 1 to 0 for a decrease of 1. Sold All: 11 Reduced: 29 Increased: 39 New Position: 16.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $436.64 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

The stock increased 4.65% or $0.14 during the last trading session, reaching $3.15. About 625,307 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 11.53% since December 6, 2017 and is downtrending. It has underperformed by 27.15% the S&P500.

Analysts await Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings on February, 28. They expect $-0.15 earnings per share, up 11.76 % or $0.02 from last year’s $-0.17 per share. After $-0.12 actual earnings per share reported by Achillion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 25.00 % negative EPS growth.

Dafna Capital Management Llc holds 1.26% of its portfolio in Achillion Pharmaceuticals, Inc. for 947,636 shares. Great Point Partners Llc owns 2.99 million shares or 1.17% of their US portfolio. Moreover, Ecor1 Capital Llc has 1.05% invested in the company for 3.89 million shares. The New York-based Armistice Capital Llc has invested 0.74% in the stock. Rock Springs Capital Management Lp, a Maryland-based fund reported 2.35 million shares.

More notable recent Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news were published by: Globenewswire.com which released: “Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer – GlobeNewswire” on August 15, 2018, also Globenewswire.com with their article: “Achillion Appoints Dr. Steven Zelenkofske as Chief Medical Officer and Further Strengthens Clinical Development Team – GlobeNewswire” published on August 21, 2018, Seekingalpha.com published: “FDA accepts priority review of ALXN1210 as a treatment for patients with PNH in the US – Seeking Alpha” on August 20, 2018. More interesting news about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) were released by: Zacks.com and their article: “Achillion Pharmaceuticals (ACHN) Shares March Higher, Can It Continue? – Zacks.com” published on August 31, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare – Seeking Alpha” with publication date: May 21, 2018.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.